SCHEMBL5153

SCHEMBL5153

CC[CH]C1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582287 0.86 ADRB2 (0.33)
SCHEMBL6689623 0.81 ADRB2 (0.31)
SCHEMBL3308458 0.80 ADRB2 (0.33)
SCHEMBL27401809 0.79
SCHEMBL4344426 0.76
SCHEMBL16193885 0.76
SCHEMBL4753 0.76
SCHEMBL5386761 0.75 SLC6A2 (0.38)
SCHEMBL4824494 0.75 KCNH2 (0.33)
SCHEMBL3308133 0.73 ADRB2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 983 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221577-A 2-Phenoxyquinoline derivative, and preparation method and application thereof 湖南中医药大学 2024-06-21 CN claimed
CN-117843566-A Polysubstituted benzene derivative, composition and use thereof 康迈迪森(北京)医药科技有限公司 2024-04-09 CN claimed
WO-2022256299-A1 7-MORPHOLINO-5-(3-PHENYL-1 H-PYRAZOL-1 -YL)-FURO[3,2-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PIKFYVE KINASE INHIBITORS FOR THE TREATMENT OF E.G. AMYOTROPHIC LATERAL SCLEROSIS (ALS) Verge Analytics, Inc. (US) 2022-12-08 WO claimed
CN-108948019-B Focal adhesion kinase inhibitors and uses thereof 广东东阳光药业有限公司 2022-07-08 CN claimed
CN-114616232-A Azepadinopyrimidine derivatives and medical application thereof 正大天晴药业集团南京顺欣制药有限公司 2022-06-10 CN claimed
US-20210330678-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US claimed
EP-3846808-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-07-14 EP claimed
CN-111344013-A Use of NOX inhibitors for the treatment of cancer 吉恩基奥泰克斯瑞士股份有限公司 2020-06-26 CN claimed
CN-107011312-B Jungermanniaceae D nitrogen containing derivative and preparation method thereof and the purposes in treatment tumor disease 山东大学 2019-04-30 CN claimed
EP-3072890-B1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy MEI PHARMA INC (US) 2018-10-17 EP claimed
US-20030022925-A1 Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence LABORATORIOS DEL DR. ESTEVE, S.A. 2003-01-30 US claimed
US-20020147198-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2002-10-10 US claimed
WO-2002068406-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS AMGEN INC. (US) 2002-09-06 WO claimed
WO-2002066470-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2002-08-29 WO claimed
WO-2001030768-A9 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS INC (US) 2002-08-15 WO claimed
EP-1226129-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES Cytokinetics, Inc. (US) 2002-07-31 EP claimed
WO-2002055501-A2 N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AMGEN INC (US) 2002-07-18 WO claimed
WO-2001098278-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS, INC. (US) 2001-12-27 WO claimed
WO-2001030768-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS, INC. (US) 2001-05-03 WO claimed
EP-1086682-A2 UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2001-03-28 EP claimed